"Drugmakers are now getting some pushback from the public in response to their claims that they need the money, but they fall back on the rhetoric of the free market. They are investor-owned businesses, after all, they say, and they have a right to charge whatever the market will bear (which for desperately sick patients or their insurers is quite a lot). But the pharmaceutical market is hardly an example of unfettered capitalism, because the companies are totally dependent on government support. In addition to receiving huge tax breaks and government-granted exclusive marketing rights, they are permitted to acquire drugs that resulted from NIH-funded university research."
Issues and developments related to ethics, information, and technologies, examined in the ethics and intellectual property graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology" will be published in Summer 2025. Kip Currier, PhD, JD
Showing posts with label exclusive marketing rights. Show all posts
Showing posts with label exclusive marketing rights. Show all posts
Saturday, October 17, 2015
Why do drug companies charge so much? Because they can.; Washington Post, 9/25/15
Marcia Angell, Washington Post; Why do drug companies charge so much? Because they can. :
Subscribe to:
Posts (Atom)